Ivor Royston
2021
In 2021, Ivor Royston earned a total compensation of $5.7M as President and Chief Executive Officer at Sunesis Pharmaceuticals, a 666% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $255,825 |
|---|---|
| Option Awards | $3,432,238 |
| Salary | $556,283 |
| Stock Awards | $1,442,371 |
| Other | $10,427 |
| Total | $5,697,144 |
Royston received $3.4M in option awards, accounting for 60% of the total pay in 2021.
Royston also received $255.8K in non-equity incentive plan, $556.3K in salary, $1.4M in stock awards and $10.4K in other compensation.
Rankings
In 2021, Ivor Royston's compensation ranked 2,232nd out of 12,406 executives tracked by ExecPay. In other words, Royston earned more than 82.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,232 out of 12,406 | 82nd |
Division Manufacturing | 873 out of 5,494 | 84th |
Major group Chemicals And Allied Products | 332 out of 2,369 | 86th |
Industry group Drugs | 287 out of 2,090 | 86th |
Industry Pharmaceutical Preparations | 185 out of 1,537 | 88th |
Source: SEC filing on April 27, 2022.
Royston's colleagues
We found three more compensation records of executives who worked with Ivor Royston at Sunesis Pharmaceuticals in 2021.